No Data
No Data
No Data
No Data
No Data
Aibo Healthcare (688050.SH): Product passed a special review process for innovative medical devices
Gelonghui, April 2 | Aibo Medical (688050.SH) announced that the company's “artificial lens” recently passed the Special Examination Procedure for Innovative Medical Devices by the Medical Device Technology Review Center of the State Drug Administration (Innovation Review Acceptance Number: CQTS2400048). This product is an artificial lens with the effect of extending depth of field. While providing farsightedness comparable to that of ordinary single-focus intraocular lenses, patients can benefit from useful medium- and near-vision. Currently, all domestic depth-of-field intraocular lens products rely on imports. The extended depth of field intraocular lens products developed by the company is based on many innovations
Gelonghui FinanceApr 2 04:40 ET
Aibo Healthcare (688050.SH): A total cost of 2004 million yuan to buy back 0.14% of shares
Gelonghui, April 1 | Aibo Healthcare (688050.SH) announced that as of March 31, 2024, the company had repurchased 142,800 shares of the company's shares through centralized bidding transactions, accounting for 0.14% of the company's total share capital of 105,250,992 shares. The highest price of the repurchase transaction was 147.90 yuan/share, the lowest price was 134.10 yuan/share, and the total amount of capital paid was RMB 20,043,605.54 (excluding transaction fees such as stamp duty and transaction fees).
Gelonghui FinanceApr 1 08:35 ET
Aibo Healthcare (688050.SH): No partnership with Nvidia
GLONGHUI March 26 丨 Aibo Healthcare (688050.SH) said on the investor interactive platform that the company has no cooperation with Nvidia.
Gelonghui FinanceMar 26 04:03 ET
Aibo Healthcare (688050.SH): Data such as performance guidelines are disseminated online as false information
GLONGHUI March 26 | Aibo Healthcare (688050.SH) said on the investor interactive platform that data such as the performance guidelines were untrue information disseminated online. The company values investors' right to fair access to company information. The company's important matters will be promptly disclosed to all investors in the form of temporary announcements, and there is no information that should be disclosed but not disclosed. For company performance information, please refer to quick reports, forecasts and regular performance reports. The company has not mentioned any performance guidelines or other data to the outside world. For research by the company's reception agency, please refer to the “Investor Relations Activity Record Form” published by the company on the official platform.
Gelonghui FinanceMar 26 04:01 ET
Aibo Healthcare (688050.SH): Actively adjusting production line capacity in the first quarter, overall operating performance continued the past growth trend
Ge Longhui, March 15 | Aibo Healthcare (688050.SH) recently said during a survey receiving institutional investors that currently the company's two main business products have obvious off-peak season characteristics. Cataract surgery is generally in the peak season in the second and fourth quarters, while OK Mirroring is in the peak season in the first and third quarters. Although this rule has weakened in the past few years due to the pandemic, it has gradually resumed in the second half of 2023. Based on sales and production experience, the company actively adjusted production line capacity in the first quarter and collaborated to promote sales business. Overall business performance continued the growth trend of the past.
Gelonghui FinanceMar 15 04:04 ET
Aibo Healthcare (688050.SH): Self-developed high-comfort silicone hydrogel white sheets are in clinical trials
Gelonghui, March 15 | Aibo Healthcare (688050.SH) recently said during a survey receiving institutional investors that silicon hydrogel materials have higher oxygen permeability and are more comfortable. The company will use the experience accumulated in the early development and production of products such as artificial lenses, corneal contouring lenses, and pupils to continue to improve the manufacturing process of high-comfort silicon hydrogel white film products. Currently, the company's self-developed high-comfort silicon hydrogel white film is in the clinical trial stage, and the progress is in line with the company's expectations. Fujian Youyoukang, a holding subsidiary of the company, has obtained a silicon hydrogel white film registration certificate and is currently undergoing production under the coordination of the group's R&D team
Gelonghui FinanceMar 15 04:03 ET
No Data
No Data